Jakob Dupont's Insider Trades & SAST Disclosures

Jakob Dupont's most recent trade in Bolt Biotherapeutics Inc was a trade of 1,100 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 27, 2025.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Bolt Biotherapeutics Inc
Jakob Dupont Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 May 2025 1,100 1,100 - - Stock Option (Right to Buy)
Bolt Biotherapeutics Inc
Jakob Dupont Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 May 2025 20,000 20,000 - - Stock Option (Right to Buy)
Pyxis Oncology Inc
Jakob Dupont Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Mar 2025 36,979 36,979 - - Stock Option (Right to Buy)
Bolt Biotherapeutics Inc
Jakob Dupont Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Sep 2024 50,000 50,000 - - Stock Option (Right to Buy)
Bolt Biotherapeutics Inc
Jakob Dupont Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Sep 2024 16,984 16,984 - - Stock Option (Right to Buy)
Pyxis Oncology Inc
Jakob Dupont Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Mar 2024 38,741 38,741 - 0 Common Stock
Pyxis Oncology Inc
Jakob Dupont Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Aug 2023 17,250 17,250 - - Stock Option (Right to buy)
Pyxis Oncology Inc
Jakob Dupont Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Aug 2023 5,879 5,879 - - Stock Option (Right to buy)
Pyxis Oncology Inc
Jakob Dupont Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Aug 2023 3,534 3,534 - - Stock Option (Right to buy)
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Sale of securities on an exchange or to another person at price $ 3.63 per share. 02 Mar 2023 5,074 290,794 (0%) 0% 3.6 18,403 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 317,987 317,987 - - Employee Stock Option (Right to Buy)
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 141,328 295,868 (0%) 0% 0 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Sale of securities on an exchange or to another person at price $ 5.03 per share. 16 Aug 2022 4,124 158,882 (0%) 0% 5.0 20,760 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Sale of securities on an exchange or to another person at price $ 5.32 per share. 17 May 2022 3,873 163,006 (0%) 0% 5.3 20,597 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2022 147,573 147,573 - - Employee Stock Option (Right to Buy)
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2022 78,506 169,100 (0%) 0% 0 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Sale of securities on an exchange or to another person at price $ 9.86 per share. 01 Mar 2022 2,221 166,879 (0%) 0% 9.9 21,890 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.58 per share. 10 Feb 2022 5,000 95,594 (0%) 0% 9.6 47,900 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 10 Feb 2022 5,000 257,500 - - Employee Stock Option (Right to Buy)
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Sale of securities on an exchange or to another person at price $ 16.00 per share. 10 Feb 2022 5,000 90,594 (0%) 0% 16 80,000 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Sale of securities on an exchange or to another person at price $ 16.01 per share. 03 Jan 2022 5,000 90,594 (0%) 0% 16.0 80,050 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 03 Jan 2022 5,000 262,500 - - Employee Stock Option (Right to Buy)
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.58 per share. 03 Jan 2022 5,000 95,594 (0%) 0% 9.6 47,900 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Sale of securities on an exchange or to another person at price $ 17.12 per share. 16 Nov 2021 2,199 90,594 (0%) 0% 17.1 37,640 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Sale of securities on an exchange or to another person at price $ 16.41 per share. 02 Nov 2021 5,000 92,793 (0%) 0% 16.4 82,050 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 02 Nov 2021 5,000 272,500 - - Employee Stock Option (Right to Buy)
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.58 per share. 02 Nov 2021 5,000 97,793 (0%) 0% 9.6 47,900 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Sale of securities on an exchange or to another person at price $ 12.53 per share. 17 Aug 2021 2,152 92,793 (0%) 0% 12.5 26,969 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Sale of securities on an exchange or to another person at price $ 14.55 per share. 18 May 2021 5,184 94,945 (0%) 0% 14.5 75,427 Common Stock
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2021 81,327 81,327 - - Employee Stock Option (Right to Buy)
Atara Biotherapeutics Inc
Jakob Dupont EVP, Head of R&D Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2021 53,879 100,129 (0%) 0% 0 Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades